Sagimet Biosciences Inc. develops clinical-stage fatty acid synthase (FASN) inhibitors for diseases tied to dysfunctional metabolic and fibrotic pathways. Company news centers on denifanstat, an oral FASN inhibitor studied in metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne, and TVB-3567, a second oral FASN inhibitor for acne.
Recurring updates include clinical and preclinical data presentations, FASCINATE-2 analyses, regulatory and license-partner developments, financial results, capital-structure disclosures, executive leadership changes, inducement grants, shareholder matters, and investor conference participation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.